Natco Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Natco Pharma share price today

Natco Pharma (NSE: NATCOPHARM) is the special-situations specialist of Indian pharma — the company that challenges patents (Para-IV filings), wins first-to-file windfalls, and books profits in lumps that make its quarterly chart look like a seismograph. Its greatest hit, generic Revlimid in the US, produced two windfall years. That windfall has now run off — management called Revlimid’s June-quarter contribution negligible — and the stock trades at 9.9 times FY26 earnings, 12.3 times the latest four quarters and 1.48 times book.

Research date: 3 November 2026. Prices and ratios in the article text use the NSE close of ₹785.75 on 2 November 2026 — 14.7% below the ₹921 of the August research date and more than a third below the 52-week high. The latest results are Natco’s Q1 FY27 (June 2026 quarter) figures, approved on 14 August 2026. The FY26 and trailing P/E and the P/B use as-reported per-share figures on the pre-rights 17.91 Cr shares; on the enlarged 19.62 Cr shares after the rights allotment of 23 October 2026, the market value is about ₹15,414 Cr: 10.9 times FY26 profit and 13.5 times trailing profit. Balance-sheet figures are the latest disclosed, from before the rights money arrived. The September-quarter (Q2 FY27) results are due at a board meeting on 13 November 2026, after this research date, and are not reflected here.

The question that decides everything: is this a value trap (earnings cliff, cheap for a reason) or a coiled spring (the next catalysts already funded and filed)? Both cases are strong. Here is the arithmetic for each.

The model: hunt windfalls, bank them, repeat

Natco does not sell volume generics. It files patent challenges on complex, high-value drugs, partners with US majors (Teva, Lupin, Dr. Reddy’s, Alvogen), and shares the exclusivity profits when it wins. Between windfalls it runs domestic oncology, a crop-health science business (chlorantraniliprole), APIs and emerging-market formulations.

The consequence is structural lumpiness — look at the four quarters to June 2026: profits of ₹518 Cr, ₹151 Cr, ₹269 Cr (₹115 Cr of it a one-time tax benefit) and ₹206.5 Cr. Smooth quarters are not on offer here; anyone pricing it on one quarter, in either direction, is doing it wrong.

The cliff, visible in the annual numbers

From Screener.in and the company’s results, consolidated. EPS is as reported, on the share count before the October 2026 rights issue; the TTM row covers the four quarters to June 2026:

Year	Sales (₹ Cr)	OPM	Net profit (₹ Cr)	EPS (₹)
FY23	2,707	35%	715	39.18
FY24	3,999	44%	1,388	77.51
FY25	4,430	50%	1,883	105.26
FY26	4,078	36%	1,418	79.20
TTM (Jun 2026)	3,485	30%	1,145	63.89

FY25 was the Revlimid peak; FY26 was the descent beginning — sales −8%, profit −25% — and the four quarters to June 2026 take profit down another 19%. The US Revlimid opportunity has faded to a tail as full genericisation arrived. Management’s FY27 guidance — about ₹750 Cr of profit — is roughly where Natco stood in FY23 (₹715 Cr), and 47% below FY26. The falling is no longer an assumption the market makes; it is in the company’s own guidance. The debate has moved on to what rebuilds earnings from FY28, and at what price.

Q1 FY27, result by result (board meeting of 14 August 2026; figures from the results filing with NSE, the company’s press release and its earnings call the same day):

• Total revenue ₹794.4 Cr, down 43% year-on-year; profit ₹206.5 Cr, down 57% (₹1,390.6 Cr and ₹480.3 Cr a year earlier); EPS ₹11.53 against ₹26.84. Against the March quarter stripped of its ₹115 Cr one-time tax benefit, profit rose 34%.
• International formulations ₹477.1 Cr, down 57% from ₹1,120.9 Cr — the Revlimid run-off, which management now calls negligible. Underneath it, Brazil grew 180% to ₹178 Cr and Canada contributed about ₹56 Cr.
• Domestic formulations ₹136.4 Cr, up 27%. Management put the usual run-rate at about ₹107 Cr a quarter and expects to hold roughly ₹130 Cr, with semaglutide a large part of the lift — including third-party orders it does not expect to repeat.
• API ₹66.7 Cr (up 27%) and crop health ₹40.8 Cr (up 18%). Crop health still lost money in the quarter; the target is break-even for the year, with the September quarter its strongest season.
• Adcock Ingram’s share of profit ₹84.3 Cr — about 41% of Natco’s quarter, at the 35.75% stake held until July. Management put that down to a strong South African flu season and said ₹35–40 Cr is a normal quarter at that stake; Adcock itself earned ₹242.2 Cr on revenue of ₹1,582.8 Cr.
• EBITDA including other income ₹245.7 Cr, a 30.9% margin. The tax rate ran high because Brazil, taxed at more than 35%, made a larger contribution.
• Guidance: about ₹750 Cr of profit and ₹3,300–3,400 Cr of gross sales for FY27, unchanged — management told analysts not to annualise the Adcock bump. An interim dividend of ₹1.50 a share was declared (record date 20 August 2026).

What Natco bought with the windfall

This is the part the cliff-watchers miss — the balance sheet redeployment is already happening:

• Adcock Ingram, South Africa’s #2 pharma company: Natco now owns 49%, built in two purchases — 35.75% from November 2025 and the final 13.25% block in July 2026 — for ZAR 5,702 million in all, equivalent to ₹3,056 Cr at the letter of offer’s rate of ₹5.36 to the rand; the July block alone cost ZAR 1,814.74 million, recorded as ₹1,060 Cr in the 14 August results. This converts windfall cash into a durable, cash-generating consumer-pharma earnings stream. The other shareholder, Bidvest, has not offered its stake, management says, though Natco holds a right of first refusal.
• The semaglutide prize, smaller so far than the headline: the blockbuster diabetes/obesity molecule came off patent in India in 2026, and Natco launched in the first wave with vertically integrated API — a pen in several SKUs, and what it describes as the most affordable GLP-1 on the market, in vial and pen form. On the August call management called the Indian market “cutthroat”: the brand sells about ₹2 Cr a month and makes little money. The bigger prizes sit further out. The rights-issue letter of offer lists US generic Ozempic and Wegovy among Natco’s sole first-to-file opportunities (in the US, partners handle litigation and sales), while there is no filing in Canada or Brazil and the South African dossier is still some way off.
• Pipeline shots: tentative US approval for generic olaparib arrived in July 2026; in August management said the patent trial was due within months and that whether its first-to-file exclusivity survives has not yet been decided. Generic carfilzomib, which an analyst on the call placed in calendar 2027 under a settlement, remains on track by management’s account, with the plant being upgraded ahead of it and the work due to finish by year-end; management also says two exclusive US launches, unnamed for confidentiality, are planned for FY28. The letter of offer counts 28 Paragraph IV filings, including 20-plus first-to-file applications, 17 of which have tentative or final approval — classic Natco: file, litigate, wait, collect.
• A ₹1,279 Cr rights issue: 1,70,58,082 new shares at ₹750 — two for every 21 held on 1 October — allotted on 23 October 2026, taking the share count from 17.91 Cr to 19.62 Cr. The letter of offer earmarks ₹810.5 Cr of the estimated ₹1,259 Cr net proceeds for repaying debt, ₹110 Cr for R&D and ₹338.5 Cr for unidentified acquisitions and general corporate purposes; in August management spoke of one smaller acquisition opportunity in India and a very large one abroad. The 2 November close is 4.8% above the issue price.
• Net of it all: at March 2026, ₹3,127 Cr of investments on the books, borrowings of ₹714 Cr and FY26 free cash flow of ₹1,379 Cr. After the second Adcock payment, management put net cash at about ₹1,400 Cr on 14 August; consolidated borrowings stood at ₹954 Cr on 31 August, before the rights money arrived.

Shareholding

Promoters (the Nannapaneni family) held 49.39% at 30 September 2026, a stake that had drifted down only marginally over years. The rights issue moved it: the promoter group took up 22,11,776 of the new shares (₹166 Cr at ₹750), roughly a quarter of its entitlement, and the post-allotment shareholding puts it at 46.22%. Domestic institutions rose from 6.16% to 10.82% across the same two filings; FIIs hold 15.37% and the public 27.59%. About four lakh shareholders (4,04,384) own a piece of the lumpiest compounder in pharma. This page reported no promoter pledge in August; that has not been re-checked since the rights issue.

Natco Pharma share price target 2026 to 2030

EPS base ₹79.20 (FY26). Bear: the Revlimid tail vanishes faster than new launches replace it — EPS grinds down to ~₹55 by 2030, and a value-trap 9× applies: ₹495. Base: semaglutide plus Adcock consolidation plus the oncology/crop base roughly offset the cliff and grow modestly — EPS ~₹95 at 12×: ₹1,140. Bull: semaglutide scales across markets while another Para-IV hits — EPS ~₹130 at 15×: ₹1,950.

From the 2 November close of ₹785.75 the base case is ~+45% by 2030 — it was ~+24% from ₹921 in August; the bear case now sits 37% below the close and the bull case 148% above it. That is still modest over four years, because the base assumes the catalysts merely offset the cliff. The real attraction is the skew: at 1.48× June-2026 book (about 1.43× once the rights money is counted, on book value of roughly ₹550 a share), the bear case is cushioned by assets, while either semaglutide scaling or one more Para-IV win rewrites the bull column overnight. The case rests on the skew, not the certainty.

Two things have moved underneath these scenarios since August, and we have deliberately left the assumptions unchanged in this refresh. First, the share count: the scenario EPS levels were set when Natco had 17.91 Cr shares; it now has 19.62 Cr, so the same per-share figure needs about 9.5% more total profit than it did in August. Second, management’s FY27 guidance of about ₹750 Cr of profit works out to ₹38–42 a share, depending on whether the new shares are counted — below the ₹55 the bear case assumes for 2030, and less than half the base case’s ₹95. At the 2 November close the stock is roughly 19–21 times that guidance. The September-quarter results on 13 November are the next evidence on which set of numbers is the better guide.

What supports the case

1. 9.9× FY26 earnings and 1.48× book at ₹785.75 — on the historical numbers the cliff is priced; the catalysts largely are not. (On the four quarters to June 2026 the multiple is 12.3×, and on FY27 guidance roughly 19–21×.)
2. Semaglutide, first wave, vertically integrated — still a legitimate long-dated shot at the decade’s biggest generic opportunity: the US generic Ozempic and Wegovy filings are sole first-to-file, even if the Indian launch makes little money so far.
3. 49% of Adcock Ingram — windfall cash converted into a durable second earnings base, not buybacks and vanity; it supplied about 41% of June-quarter profit, flu season included.
4. Serial windfall-hunter with a 25-year record: Revlimid was not the first and is unlikely to be the last — 28 Paragraph IV filings, 17 first-to-file applications already with tentative or final approval.
5. Modest debt — ₹954 Cr at 31 August 2026, with ₹810.5 Cr of the rights money earmarked to repay it — ₹1,379 Cr of FY26 free cash flow, and a promoter group still holding 46.22% after the rights issue.
6. R&D of ₹408.6 Cr in FY26, about 10% of consolidated revenue, behind a US pipeline of 25-plus products; management says 70–80% of the spend is aimed at launches between 2028 and 2035.

Risks, plainly: the cliff is certain while the catalysts are probabilistic, and management’s own FY27 guidance puts this year’s earnings below the bear case’s 2030 level; quarterly lumpiness will repeatedly look like collapse; semaglutide competition in India is already intense enough that management is waiting for prices to stabilise; Adcock brings currency and integration risk, and its June-quarter boost came from a flu season; the rights issue added 9.5% more shares, with about a quarter of the net proceeds earmarked for unidentified acquisitions and general corporate purposes; and FY26’s ₹1,418.5 Cr profit included a one-time ₹115 Cr tax benefit from the move to the new tax regime.

What to weigh at the current price

The Revlimid decline is visible and unavoidable; replacement growth from semaglutide, Adcock Ingram and new Para-IV launches is less certain. That gap between a known earnings cliff and several valuable but probabilistic catalysts is the stock’s defining tension.

The September-quarter results on 13 November are the first clean read on the post-Revlimid base: whether domestic formulations hold the ₹130 Cr a quarter management expects, what Adcock contributes at 49% against management’s “normal” of about ₹100 Cr of Adcock profit a quarter (roughly ₹49 Cr to Natco), whether crop health’s strongest season puts it on course for full-year break-even, and whether the ₹750 Cr profit guidance survives. Beyond the quarter, the olaparib trial and exclusivity decision and the carfilzomib launch decide whether the bull column has its next windfall to point to.

FAQ

What is the Natco Pharma share price target for 2030? The table above presents bear, base and bull scenarios for every year to 2030. The 2030 figures are approximately ₹495, ₹1,140 and ₹1,950 on the assumptions shown above, which were left unchanged at the 3 November 2026 research date.

Why is Natco Pharma so cheap? On past earnings it is — 9.9 times FY26 at the 2 November close. But its biggest profit engine (US generic Revlimid) has wound down to a negligible contribution, FY26 profit fell 25%, and management’s FY27 guidance of about ₹750 Cr implies a further 47% fall; on that guidance the stock is roughly 19–21 times earnings. The debate is whether semaglutide, Adcock Ingram and the pipeline rebuild earnings from FY28.

What is Natco’s semaglutide opportunity? The diabetes/obesity blockbuster lost Indian patent protection in 2026. Natco is among the first-wave launchers with its own API, but management describes the Indian market as fiercely competitive, with its brand selling about ₹2 Cr a month. Further out, its US generic Ozempic and Wegovy filings are sole first-to-file, with partners handling litigation and sales; Natco has not filed in Canada or Brazil.

What did Natco buy in South Africa? A 49% stake in Adcock Ingram, South Africa’s second-largest pharma company, built in two purchases (35.75% from November 2025, 13.25% in July 2026) for about ₹3,000 Cr in all, according to the rights-issue letter of offer — redeploying windfall cash into durable earnings. Its share of Adcock’s profit was ₹84.3 Cr in the June 2026 quarter, about 41% of Natco’s total.

When are Natco’s next results? The board meets on Friday, 13 November 2026, to consider results for the quarter and half-year ended 30 September 2026 and a second interim dividend, if any (company notice to the exchanges, 29 October 2026); the results calendar tracks the date. Expect lumpiness; judge the year, not the quarter.

Change log

• 3 November 2026 — Refreshed after the Q1 FY27 (June 2026 quarter) results of 14 August 2026 and the October 2026 rights issue; the Q2 FY27 results are due on 13 November 2026 and are not included. Price updated from ₹921 (5 August) to the NSE close of ₹785.75 on 2 November 2026. P/E on FY26 EPS (₹79.20, unchanged) moves from 11.6× to 9.9×; added the trailing figure of 12.3× on EPS of ₹63.89 for the four quarters to June 2026 (both on as-reported EPS, before the rights issue), the market value on the enlarged share count (about ₹15,414 Cr, 13.5 times trailing profit) and the multiple on management’s FY27 profit guidance. Book value input in the article text updated from ₹515 (March 2026) to ₹532.55 (June 2026), so price-to-book moves from 1.78× to 1.48×. Base-case 2030 upside restated from ~+24% to ~+45%. Scenario EPS levels, multiples and the year-by-year grid are unchanged — they are assumptions, not market inputs — and the text now flags that they were set on the pre-rights share count and that FY27 guidance sits below the bear case’s 2030 EPS. Added Q1 FY27 result-by-result commentary, a TTM row in the annual table, the rights issue (1,70,58,082 shares at ₹750, allotted 23 October 2026; shares 17.91 Cr to 19.62 Cr), borrowings of ₹954 Cr at 31 August 2026, and the post-allotment shareholding (promoter group 49.39% to 46.22%). Updated the semaglutide, olaparib and carfilzomib commentary from the August earnings call and the letter of offer. Corrected the Adcock Ingram investment from “roughly ₹2,300 Cr” to about ₹3,000 Cr (ZAR 5,702 million), per the rights-issue letter of offer, and FY26’s operating margin in the annual table from 35% to 36%, per Screener. Removed the EV/EBITDA and PEG figures, which no longer reflected current data, from the article text; the dated fundamentals box (as of 5 Aug 2026) is unchanged. Made the FY26 tax-rate point specific (a ₹115 Cr one-time benefit) and reworded two lines that read as instructions to investors (on position sizing and on who should own the stock) as analysis.
• 15 August 2026 — Editorial-voice refresh; no figures changed.
• 5 August 2026 — Published on FY26 results: FY26 EPS ₹79.20, price ₹921, P/E 11.6×.

Sources

• NATCO Pharma, outcome of the board meeting of 14 August 2026, filed with NSE — Q1 FY27 results, press release, the ₹1.50 interim dividend and the July 2026 Adcock Ingram purchase (note 7 to the consolidated results); the press release and limited review reports (which include the results statements) on the company’s site.
• NATCO Pharma, transcript of the Q1 FY27 earnings call held on 14 August 2026, filed with the exchanges on 18 August 2026 — guidance, segment commentary, net cash, Adcock Ingram’s normal quarterly profit, semaglutide, olaparib and carfilzomib.
• NATCO Pharma press releases for Q2 FY26 (14 November 2025), Q3 FY26 (12 February 2026) and Q4 FY26 (29 May 2026) — quarterly profits, FY26 profit of ₹1,418.5 Cr and the ₹115 Cr one-time tax credit.
• NATCO Pharma, letter of offer for the rights issue, dated 28 September 2026, filed with NSE (company copy) — issue terms, objects of the issue, the cost of the 49% Adcock Ingram stake, borrowings at 31 August 2026, summary financials (EPS and net asset value per share for FY26, Q1 FY26 and Q1 FY27), R&D spend and the US pipeline.
• NATCO Pharma, allotment of rights equity shares, 23 October 2026 (company copy), and promoter-group disclosures under Regulation 29(2) of the SEBI takeover regulations, 29 October 2026, filed with BSE.
• NATCO Pharma, notice of the board meeting on 13 November 2026, dated 29 October 2026, filed with BSE.
• Screener.in, NATCOPHARM — annual sales, margins and profit, trailing-twelve-month sales and margin, and shareholding at 30 September 2026 and after the rights allotment (checked 3 November 2026).
• NSE end-of-day files for 2 November 2026 — the close of ₹785.75 and the distance from the 52-week high shown in the technical panel above.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises — patent litigation, drug pricing and market shocks can push prices outside every band shown. Do your own research and consult a registered adviser before acting.